Sanofi’s Toujeo – a follow-up to its long-acting insulin drug Lantus – has underperformed commercially since launch but the company hopes new data could help it gather momentum. The French ...

Sanofi has launched its new insulin treatment Toujeo in the UK, and says it will be priced at the same level as its big seller Lantus. The pricing decision matches Sanofi's approach in the US ...

How TIME and Statista Determined the World's Most Sustainable Companies of 2025 In the fight against climate change, ...

A nonprofit is nearing completion on a facility that will make generic versions of three types of insulin. It will sell them for no more than $30 a vial.

While there is no clear evidence that GLP-1 medications can increase chances of pregnancy, there is a strong correlation ...

Toujeo is a once-daily, long-acting basal analog insulin that improves glycemic control in adults with type 1 and type 2 diabetes.In 2019, Sanofi launched Combiflam Plus (Paracetamol and Caffeine ...

Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards ...

Sanofi India Share Price Today 7 Jul 2025: Track Sanofi India share price today on NSE/BSE with real-time updates. Check stock performance, fundamentals, market cap, shareholding, financial ...